Is It Anxiety — or Is It Perimenopause? How to Tell, and Why It Matters
Many women in their 40s develop anxiety symptoms they've never had before — free-floating dread, sudden panic, a sense of doom that has no obvious cause. When anxiety emerges in perimenopause, it requires a different clinical lens than anxiety arising at other life stages. Understanding the difference changes treatment.
By Dr. Julie Rashkis, Psy.D. | Licensed Psychologist | Menopause Society Certified Practitioner | therapyformidlife.com
'I've never been an anxious person. I've always been the calm one in the room. And now I wake up at 3am with my heart pounding and this feeling that something terrible is about to happen — and I have no idea what. I've Googled everything. My doctor says my thyroid is fine. I don't know what's wrong with me.'
This is one of the most common presentations I see in perimenopausal women — and one of the most frequently misread. New-onset anxiety in the 40s is so common during perimenopause that it should prompt a hormonal evaluation as one of the first lines of clinical inquiry. Instead, many women are assessed for an anxiety disorder in isolation, handed a prescription, and sent on their way without anyone asking what their cycle has been doing, when the anxiety started in relation to their perimenopausal symptoms, or whether there is a hormonal driver underlying what looks, from the outside, like straightforward generalized anxiety.
This article explains what perimenopause does to the anxiety system, how to distinguish hormonally-driven anxiety from primary anxiety disorders, and why that distinction matters enormously for treatment. It also addresses one of the most confusing and frightening symptoms of the transition: the overlap between hot flashes and panic attacks — two experiences so similar they are routinely confused for each other, with significant consequences for how women are treated.
How Perimenopause Creates an Anxiety-Prone Brain
The anxiety system in the brain is not a single structure but a network — the hypothalamic-pituitary-adrenal (HPA) axis, the amygdala, the prefrontal cortex, and the neurotransmitter systems connecting them. Estrogen and progesterone both play regulatory roles in this network, and their disruption during perimenopause produces measurable changes in how the brain processes threat, uncertainty, and stress.
Estrogen has an inhibitory effect on the release of cortisol, the primary stress hormone. When estrogen is stable and adequate, it moderates the HPA axis response to stressors — the system activates appropriately and then recovers. As estrogen fluctuates unpredictably in perimenopause, this regulatory brake is removed. The HPA axis becomes hyperreactive: it activates more easily, releases more cortisol, and recovers more slowly. The physiological result is a state of chronic background hyperarousal — the nervous system is running at a higher baseline activation level, primed for threat, even when none is present. The subjective experience of this state is precisely what women describe: a persistent sense of unease, dread without object, feeling 'on edge' for no reason they can name.
Progesterone's role is equally important. Its metabolite allopregnanolone is a powerful positive modulator of GABA-A receptors — the brain's primary inhibitory, calming system. As progesterone declines and ovulation becomes irregular during perimenopause, allopregnanolone levels fall. The result is a reduction in the brain's intrinsic anxiety buffer. Situations that would previously have produced manageable worry now produce heightened distress. The capacity for 'background calm' — the low-level feeling of okayness that most people take for granted — is reduced.
These neurobiological changes are compounded by the sleep disruption of perimenopause. The HPA axis is acutely sensitive to sleep deprivation; inadequate sleep raises baseline cortisol and further sensitizes the stress response system. For many perimenopausal women, what presents as anxiety is substantially driven by the cascade: hot flashes disrupt sleep, sleep deprivation dysregulates the HPA axis, cortisol rises, and the nervous system remains in a state of heightened activation that produces anxiety symptoms.
"The SWAN study followed 2,956 women over ten years and found that even women with low baseline anxiety were 56-61% more likely to develop high anxiety during early or late perimenopause than during premenopause — even after controlling for vasomotor symptoms, life stressors, and health factors." — Bromberger et al., Menopause (2013)
What Perimenopausal Anxiety Looks Like — and How It Differs from Classic GAD
Perimenopausal anxiety has a recognizable clinical profile that is worth distinguishing from the presentation of generalized anxiety disorder (GAD) arising at other life stages.
Feature: Onset
Perimenopausal anxiety: New onset in mid-to-late 40s, often with no prior history of significant anxiety
Primary GAD: Often has earlier onset; chronic worry pattern typically present for years
Feature: Cycle relationship
Perimenopausal anxiety: Often worse in luteal phase or around irregular periods; fluctuates with hormonal changes
Primary GAD: Not typically linked to menstrual cycle phase
Feature: Quality
Perimenopausal anxiety: Often described as physical dread without an obvious cause; sense of doom; may feel more somatic than cognitive
Primary GAD: Typically involves identifiable worry themes; tends to be more cognitive in character
Feature: Co-occurring symptoms
Perimenopausal anxiety: Frequently co-occurs with hot flashes, sleep disruption, irritability, brain fog, or irregular cycles
Primary GAD: May occur without perimenopausal physical symptoms
Feature: 3am awakening
Perimenopausal anxiety: Very common; often accompanied by racing heart or heat and a surge of alarm with no precipitating worry thought
Primary GAD: Waking anxiety possible but often has identifiable worry content driving it
Feature: Hormonal response
Perimenopausal anxiety: May improve significantly with hormonal stabilization — which would not affect primary GAD
Primary GAD: Not expected to respond to hormonal intervention
This distinction is clinically important — not because the two are mutually exclusive (many women have both primary anxiety vulnerabilities and perimenopausal amplification), but because treatment should address what is actually driving the symptoms. Treating hormonally-driven anxiety with antidepressants alone, without addressing the hormonal substrate, is like treating a broken leg with pain medication: the pain may be reduced, but the underlying problem remains.
Hot Flashes and Panic Attacks: The Overlap Nobody Warned You About
One of the most frightening experiences many perimenopausal women report is what feels unmistakably like a panic attack — heart pounding, sweating, breathlessness, a wave of intense fear, the sense of impending doom. But is it a panic attack, a hot flash, or both? The answer is more complex than most clinical encounters acknowledge.
Hot flashes and panic attacks share a striking symptom overlap. Both involve rapid onset, palpitations, sweating, flushing, shortness of breath, and nausea. Both can strike at night, waking women from sleep. Both can be triggered by caffeine, alcohol, and stress. And both respond to some of the same treatments, including SSRIs, SNRIs, and clonidine — a convergence that hints at overlapping neurological mechanisms.
Research from a case-control study of panic disorder in women attending a menopause clinic found that 18% of participants met criteria for panic disorder — and of those, 62% reported the onset of panic disorder at the commencement of menopause (Pacchierotti et al., 2004). The SWAN study found that women with high levels of somatic anxiety had more than three times the risk of hot flashes than those with low somatic anxiety. The relationship runs in both directions: anxiety can trigger or amplify vasomotor symptoms, and vasomotor symptoms can trigger anxiety responses. The two systems are neurologically intertwined via hypothalamic pathways.
The clinical consequence is that women experiencing what they believe are panic attacks may actually be experiencing hot flashes that their anxious nervous system is interpreting as dangerous — generating genuine fear responses that compound the physiological event. And women experiencing what they believe are only hot flashes may, in some cases, be having panic attacks that carry somatic features similar to vasomotor symptoms. Without clinicians trained to ask the right questions, this overlap is almost never sorted out correctly.
"Women with high levels of somatic anxiety had more than three times the risk of hot flashes. And women with anxiety at the onset of perimenopause were five times more likely to report hot flashes than women with low anxiety — these systems are neurologically connected, not separate." — Penn Ovarian Aging Study; SWAN
Why This Gets Missed: The Misdiagnosis Problem
Women presenting with new-onset anxiety in their 40s are frequently assessed for an anxiety disorder, prescribed an antidepressant or anxiolytic, and discharged from the appointment without the word 'perimenopause' being mentioned. This happens for several reasons.
First, many clinicians — including primary care providers, psychiatrists, and even some gynecologists — are not trained to recognize perimenopausal anxiety as a distinct clinical presentation requiring hormonal evaluation. The Menopause Society has documented significant gaps in clinician education about menopause across medical specialties.
Second, standard anxiety assessment tools do not capture hormonal context. The GAD-7, the most commonly used anxiety screening instrument in primary care, asks nothing about menstrual cycle changes, vasomotor symptoms, or perimenopausal status. A woman can score in the clinically significant range on the GAD-7 and have her perimenopause completely unaddressed.
Third, many women themselves do not connect their anxiety to perimenopause — particularly if they have not yet noticed significant menstrual changes. Research consistently shows that psychological symptoms, including anxiety and irritability, often precede the onset of irregular periods by months or years. A woman in her early-to-mid 40s with regular cycles but new-onset anxiety is not 'too young' for perimenopause. She may be in its earliest stage, and the psychological symptoms may be the first signal.
What Accurate Assessment Should Include
Evaluating anxiety in a perimenopausal context requires asking questions that a standard anxiety assessment may not prompt. A comprehensive clinical picture should include:
Timing and onset. When did the anxiety start, and what else was happening hormonally? Was there a change in menstrual cycle regularity, a period of irregular spotting, the onset of hot flashes or night sweats, or any other perimenopausal symptoms around the same time the anxiety emerged?
Cycle relationship. Does the anxiety fluctuate with the menstrual cycle? Perimenopausal anxiety is often worse in the luteal phase or around the time of irregular periods. This cyclical pattern is a significant clinical indicator.
Prior reproductive hormone sensitivity. Is there a history of premenstrual mood symptoms, PMDD, postpartum depression or anxiety, or mood changes with hormonal contraceptives? Women with this history are at elevated risk for perimenopausal anxiety and depression — they are what I and other clinicians refer to as being within the 'windows of vulnerability' framework.
The physical quality of the anxiety. Is it primarily somatic — heart racing, sweating, waves of physical alarm — or primarily cognitive — chronic worry about specific topics? The predominantly somatic presentation of perimenopausal anxiety is a clinical marker.
What has and has not helped. If previous trials of standard anxiolytics or antidepressants have had limited effect, this is a signal worth examining in the context of hormonal status.
What Actually Helps Perimenopausal Anxiety
Treatment of perimenopausal anxiety should be informed by what is actually driving it — which means addressing the hormonal context alongside the psychological one.
Hormonal stabilization. For women whose anxiety is primarily hormonally driven, stabilizing erratic estrogen fluctuations through menopausal hormone therapy can directly reduce the HPA hyperreactivity and allopregnanolone deficit that are producing the anxiety. This is a conversation to have with a menopause-specialized clinician.
Cognitive Behavioral Therapy (CBT). CBT has a strong evidence base for anxiety across presentations, including perimenopausal anxiety. It directly addresses the catastrophic interpretation of somatic symptoms — helping women develop more accurate and less alarming frameworks for understanding hot flashes, palpitations, and the other physical experiences that can escalate into panic when interpreted as dangerous.
CBT for Insomnia (CBT-I). Given the sleep-HPA axis cascade driving much perimenopausal anxiety, directly treating insomnia has downstream effects on anxiety that can be substantial. CBT-I is the first-line evidence-based treatment for insomnia and is more effective than sleep medication in the long term.
Mindfulness and nervous system regulation. Research supports mindfulness-based interventions, breathing practices, and somatic regulation techniques as moderators of HPA hyperreactivity. These are not substitutes for addressing the underlying hormonal picture but are meaningful complements, particularly for managing the acute surge of anxiety that hot flashes can trigger.
Working with a psychologist who understands perimenopause. This is not a small point. The clinical value of working with a therapist who can accurately distinguish perimenopausal anxiety from primary anxiety disorder, who understands the hormonal context, and who can coordinate care with a menopause-specialized medical provider is significant. It is the kind of integrated, biopsychosocial care the research says perimenopausal mental health requires.
About the Author
Dr. Julie Rashkis is a licensed psychologist and Menopause Society Certified Practitioner — one of the only private-practice psychologists in the country to hold this dual credential. She specializes in the psychological dimensions of perimenopause, menopause, and midlife transitions, and works at the intersection of hormonal health and mental health in a way that most therapy practices do not. She is the founder of Therapy for Midlife, a virtual practice licensed in California and Wisconsin, seeing clients across all PSYPACT-participating states.
www.therapyformidlife.com | Book a free consultation
References
1. Bromberger, J. T., Kravitz, H. M., Chang, Y., Randolph, J. F., Avis, N. E., & Gold, E. B. (2013). Does risk for anxiety increase during the menopausal transition? Study of Women's Health Across the Nation (SWAN). Menopause, 20(5), 488-495. PMC3641149. 2. Freeman, E. W., & Sammel, M. D. (2016). Anxiety as a risk factor for menopausal hot flashes: Evidence from the Penn Ovarian Aging cohort. Menopause, 23(9), 942-949.
3. Pacchierotti, C., et al. (2004). Panic disorder in menopause: A case-control study. Psychoneuroendocrinology, 29(1). 4. Brinton, R. D., et al. (2015). Progesterone receptors: Form and function in brain. Frontiers in Neuroendocrinology, 36, 58-79. 5. Guennoun, R. (2020). Progesterone in the brain: Hormone, neurosteroid and neuroprotectant. International Journal of Molecular Sciences, 21(15), 5271.
6. Bromberger, J. T., & Epperson, C. N. (2018). Depression during and after the perimenopause: Impact of hormones, sleep, and menopause symptoms. Obstetrics and Gynecology Clinics of North America, 45(4), 663-678.
7. Rubinow, D. R., & Schmidt, P. J. (2019). Sex differences and the neurobiology of affective disorders. Neuropsychopharmacology, 44(1), 111-128.
8. Joffe, H., Massler, A., & Sharkey, K. M. (2010). Evaluation and management of sleep disturbance during the menopause transition. Seminars in Reproductive Medicine, 28(5), 404-421.
9. Gordon, J. L., et al. (2018). Estradiol variability, stressful life events, and the emergence of depressive symptomatology during the menopausal transition. Menopause, 25(3), 257-266.
10. Alblooshi, S., Taylor, M., & Gill, N. (2023). Does menopause elevate the risk for developing depression and anxiety? Results from a systematic review. Australasian Psychiatry, 31(3). PMC10088347.
11. Unverferth, K. (2025). Perimenopausal anxiety: Distinguishing hot flashes from panic attacks and the role of allopregnanolone. Psychopharmacology Institute CME.
